Nisa Investment Advisors LLC Lowers Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Nisa Investment Advisors LLC trimmed its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 85.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,770 shares of the company's stock after selling 10,097 shares during the period. Nisa Investment Advisors LLC's holdings in Janux Therapeutics were worth $48,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in JANX. GAMMA Investing LLC boosted its position in Janux Therapeutics by 1,574.0% during the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock valued at $45,000 after acquiring an additional 1,574 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after buying an additional 442 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Janux Therapeutics in the 4th quarter worth $59,000. FNY Investment Advisers LLC increased its stake in shares of Janux Therapeutics by 6,928.6% in the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock worth $66,000 after purchasing an additional 2,425 shares in the last quarter. Finally, KBC Group NV bought a new position in Janux Therapeutics in the 1st quarter worth $66,000. 75.39% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Raymond James Financial assumed coverage on shares of Janux Therapeutics in a research report on Friday, July 11th. They issued an "outperform" rating and a $65.00 price objective on the stock. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $91.89.

Janux Therapeutics Trading Up 1.2%

JANX traded up $0.30 on Tuesday, reaching $26.38. The company had a trading volume of 655,503 shares, compared to its average volume of 878,998. The company has a fifty day moving average of $24.62 and a 200-day moving average of $31.14. The company has a market capitalization of $1.56 billion, a P/E ratio of -19.40 and a beta of 2.86. Janux Therapeutics, Inc. has a one year low of $22.48 and a one year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Research analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Insider Activity

In other news, insider Andrew Hollman Meyer sold 3,333 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total transaction of $106,755.99. Following the sale, the insider owned 82,139 shares in the company, valued at $2,630,912.17. This represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 29.40% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.